Data / Drug companies / Unit Dose Solutions, Inc.
Unit Dose Solutions, Inc.: 87 products in the FDA NDC directory, labeler code 87441
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Unit Dose Solutions, Inc. (labeler code 87441) lists 87 products in the FDA National Drug Code Directory, covering 54 finished drugs by generic name. By type: 85 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 29, 2026.
The request: Watch Unit Dose Solutions, Inc. (FDA labeler code 87441): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 87441
- Products in commercial distribution
- 87
- Packages
- 87
- Finished drugs by generic name
- 54
- Prescription products
- 85
- Over the counter products
- 2
- Controlled substance products
- Schedule III 6, Schedule IV 10
- Started marketing in the last 12 months
- 84
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 86 | 98.9% |
| Over the counter monograph drugs | 1 | 1.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 85 | 97.7% |
| Over the counter drugs | 2 | 2.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 50 | 57.5% |
| Tablet, film coated | 17 | 19.5% |
| Capsule | 13 | 14.9% |
| Tablet, delayed release | 4 | 4.6% |
| Tablet, coated | 2 | 2.3% |
| Capsule, delayed release | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Naproxen | 87441-092 | Tablet | Generic drugs (ANDA) | September 29, 2026 |
| Lorazepam | 87441-091 | Tablet | Generic drugs (ANDA) | September 24, 2026 |
| Clonazepam | 87441-090 | Tablet | Generic drugs (ANDA) | September 24, 2026 |
| Tramadol Hydrochloride | 87441-089 | Tablet, coated | Generic drugs (ANDA) | September 23, 2026 |
| Trazodone Hydrochloride | 87441-081 | Tablet | Generic drugs (ANDA) | July 9, 2026 |
| Trazodone Hydrochloride | 87441-080 | Tablet | Generic drugs (ANDA) | July 9, 2026 |
| Topiramate | 87441-079 | Tablet, film coated | Generic drugs (ANDA) | July 9, 2026 |
| Sulfamethoxazole and Trimethoprim | 87441-078 | Tablet | Generic drugs (ANDA) | July 9, 2026 |
| Ondansetron Hydrochloride | 87441-088 | Tablet, film coated | Generic drugs (ANDA) | July 8, 2026 |
| Hydroxyzine pamoate | 87441-087 | Capsule | Generic drugs (ANDA) | July 8, 2026 |
| Methocarbamol | 87441-086 | Tablet, coated | Generic drugs (ANDA) | July 8, 2026 |
| Sertraline Hydrochloride | 87441-077 | Tablet, film coated | Generic drugs (ANDA) | July 8, 2026 |
| Sertraline Hydrochloride | 87441-076 | Tablet, film coated | Generic drugs (ANDA) | July 8, 2026 |
| Sertraline Hydrochloride | 87441-075 | Tablet, film coated | Generic drugs (ANDA) | July 6, 2026 |
| Quetiapine fumarate | 87441-074 | Tablet | Generic drugs (ANDA) | July 6, 2026 |
| Quetiapine fumarate | 87441-073 | Tablet | Generic drugs (ANDA) | July 6, 2026 |
| Quetiapine fumarate | 87441-072 | Tablet | Generic drugs (ANDA) | July 2, 2026 |
| Quetiapine fumarate | 87441-071 | Tablet | Generic drugs (ANDA) | July 2, 2026 |
| Promethazine Hydrochloride | 87441-070 | Tablet | Generic drugs (ANDA) | July 1, 2026 |
| Prednisone | 87441-069 | Tablet | Generic drugs (ANDA) | July 1, 2026 |
| Prazosin Hydrochloride | 87441-068 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Prazosin Hydrochloride | 87441-067 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Pantoprazole Sodium | 87441-066 | Tablet, delayed release | Generic drugs (ANDA) | July 1, 2026 |
| Buprenorphine | 87441-082 | Tablet | Generic drugs (ANDA) | June 30, 2026 |
| Ondansetron Hydrochloride | 87441-064 | Tablet, film coated | Generic drugs (ANDA) | June 30, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.